Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
NCT00385827 · Centocor, Inc. · PHASE2 · terminated · last registry update 2014-08-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of efficacy.” | – | Registry record, Centocor, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-08-04Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Bortezomib (NCT00401843)
- 2015-06-19Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Bortezomib (NCT01531998)
- 2014-11-18Results posted on the registry: Janssen Research & Development, LLC, Siltuximab11 mg/kg + Siltuximab 8.3 mg/kg or 11 mg/kg (NCT00911859)
- 2014-09-29Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Placebo (NCT01513317)
- 2014-09-29Also stopped (terminated): Janssen Research & Development, LLC, Siltuximab + Placebo (NCT01513317)
- 2014-08-20Results posted on the registry: Janssen Research & Development, LLC, Siltuximab + Placebo (NCT01024036)
- 2014-05-19Also stopped (terminated): Janssen Pharmaceutical K.K., Siltuximab (NCT01309412)
- 2013-12-24Phase 3 first posted: Janssen Research & Development, LLC, adalimumab 40 mg + sirukumab 100 mg (NCT02019472)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision